Main content

    Gynecologic Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Cervical Cancer  |  Endometrial Cancer  |  Ovarian / Fallopian tube / Peritoneal Cancer  |  All Tumor Types

    Active Trials

    Cervical Cancer

    Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
    Description: Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with pathologically confirmed primary cervical cancer initially treated with a standard radical hysterectomy with pelvic lymphadenectomy
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 263

    Title: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 Cervical Cancer
    Description: Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, stage IA1 (lymph-vascular space invasion [LVSI]+), IA2, and IB1 (tumor size [maximum visible or palpable]) =< 2 cm), any grade
    Status: Contact site for study status
    Contact: Kent Lai, 415-600-3613, Email: LaiKH@sutterhealth.org about Study GOG 278

    Title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
    Description: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with histologically confirmed squamous, adenosquamous, or adenocarcinoma of the cervix
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 0724

    Back to top

    Endometrial Cancer

    Title: A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
    Description: The primary purpose of this study is to determine if MLN0128 in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma)
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Millenium C31004

    Title: A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
    Description: Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histologically confirmed diagnosis of endometrial cancer and who must have undergone prior complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 238

    Title: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
    Description: Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 286B

    Back to top

    Ovarian / Fallopian tube / Peritoneal Cancer

    Title: FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer
    Description: This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Immunogen GOG3011

    Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
    Description: This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC).
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer in recurrent stage
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Mateon OX4325

    Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
    Description: This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in patients with Stage III or IV ovarian cancer.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically confirmed, advanced (FIGO Stage III or IV) high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have completed first line platinum based chemotherapy (neoadjuvant or adjuvant)
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Tesaro PRIMA

    Title: A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Description: The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Janssen ET743

    Title: A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100
    Description: This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Javelin Ovarian 100

    Title: Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
    Description: This randomized phase II trial studies how well nivolumab works with or without ipilimumab in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that has not responded after prior treatment (persistent) or has come back (recurrent)
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer with documented disease progression
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study NRG-GY003

    Title: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Description: This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study NRG-GY004

    Title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
    Description: This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory)
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, who have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study NRG-GY005

    Title: Double-Blind, Placebo Controlled, Phase III Trial of FANG TM (Adjuvant bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer
    Description: A multicenter, randomized, double-blind, placebo-controlled, Phase III study of maintenance FANG in women with Stages III/IV high-grade serous / endometrioid ovarian, fallopian tube or primary peritoneal cancer who have achieved a clinically defined complete response following primary surgery and adjuvant chemotherapy.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically confirmed Stage III/IV high-grade serous / endometrioid ovarian, fallopian tube or primary peritoneal cancer without prior therapy
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study FANG

    Title: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
    Description: Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis
    Status: Contact site for study status
    Contact: Kent Lai, 415-600-3613, Email: LaiKH@sutterhealth.org about Study GOG 225

    Title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
    Description: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with documented low-grade serous carcinoma; confirmation must occur by prospective pathology review prior to study entry; the prospective pathology review must be done on tissue from the recurrent carcinoma
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 281

    Back to top

    All Tumor Types

    Title: An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
    Description: This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages. During Stage 1, GDC-0032 will be administered every day orally (PO) and at escalating doses in participants with locally advanced or metastatic solid tumors. During Stage 2, GDC-0032 will be administered alone or as combination therapy within indication-specific cohorts. In Phase II of the study, the efficacy and safety of the combination GDC-0032 and fulvestrant will be evaluated in post-menopausal female participants with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor-positive breast cancer.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, who have histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Genentech Phase I - PMT4979G

    Title: Molecular Analysis for Therapy Choice (MATCH)
    Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, who have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study NCI-MATCH

    • updated June 2017

    Back to top